New combo aims to turn untreatable lung tumors into surgical candidates

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system * Initially unresectable disease as determined by multidisciplinary team (MDT) assessment * At least 1 measurable intrapulmonary lesion according to RECIST version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Forced expiratory volume in the first second (FEV1) \> 1.0 L and \> 40% of predicted normal value * Estimated life expectancy of at least 3 months * Adequate organ function * Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment * Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab * Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab * Ability to understand and willingness to sign a written informed consent form Exclusion Criteria: * Prior local therapy for NSCLC, including radiotherapy or interventional therapy * Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations * Distant organ metastasis * History of another malignancy within the past 5 years * Active autoimmune disease or history of autoimmune disease requiring systemic treatment * Known allergy to any study drug or excipient * Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment * Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis * Major surgery requiring general anesthesia within 4 weeks before first dose * Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk * Participation in another interventional therapeutic clinical study * Psychiatric illness or history of psychotropic drug abuse that may compromise study participation * Any condition judged by the investigator to make the patient unsuitable for the study